These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 21541671

  • 1. A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility.
    Mortensen KL, Johansen HK, Fuursted K, Knudsen JD, Gahrn-Hansen B, Jensen RH, Howard SJ, Arendrup MC.
    Eur J Clin Microbiol Infect Dis; 2011 Nov; 30(11):1355-63. PubMed ID: 21541671
    [Abstract] [Full Text] [Related]

  • 2. Susceptibility of fungi isolated from the respiratory tract of falcons to amphotericin B, itraconazole and voriconazole.
    Silvanose CD, Bailey TA, Di Somma A.
    Vet Rec; 2006 Aug 26; 159(9):282-4. PubMed ID: 16946311
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.
    Wang HC, Hsieh MI, Choi PC, Wu CJ.
    J Clin Microbiol; 2018 Oct 26; 56(10):. PubMed ID: 30093391
    [Abstract] [Full Text] [Related]

  • 4. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
    Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH.
    J Antimicrob Chemother; 2000 Aug 26; 46(2):229-34. PubMed ID: 10933645
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the activities of amphotericin B, itraconazole, and voriconazole against clinical and environmental isolates of Aspergillus species.
    Misra R, Malik A, Singhal S.
    Indian J Pathol Microbiol; 2011 Aug 26; 54(1):112-6. PubMed ID: 21393890
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
    Pfaller MA, Messer SA, Hollis RJ, Jones RN, SENTRY Participants Group.
    Antimicrob Agents Chemother; 2002 Apr 26; 46(4):1032-7. PubMed ID: 11897586
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.
    Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG.
    J Clin Microbiol; 1999 Jul 26; 37(7):2343-5. PubMed ID: 10364610
    [Abstract] [Full Text] [Related]

  • 11. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
    Kaya AD, Kiraz N.
    Mycoses; 2007 Nov 26; 50(6):447-50. PubMed ID: 17944704
    [Abstract] [Full Text] [Related]

  • 12. High prevalence of azole resistance in Aspergillus fumigatus isolates from high-risk patients.
    Fuhren J, Voskuil WS, Boel CH, Haas PJ, Hagen F, Meis JF, Kusters JG.
    J Antimicrob Chemother; 2015 Oct 26; 70(10):2894-8. PubMed ID: 26163402
    [Abstract] [Full Text] [Related]

  • 13. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
    Arikan S, Sancak B, Alp S, Hascelik G, McNicholas P.
    Med Mycol; 2008 Sep 26; 46(6):567-73. PubMed ID: 19180726
    [Abstract] [Full Text] [Related]

  • 14. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies.
    Alanio A, Sitterlé E, Liance M, Farrugia C, Foulet F, Botterel F, Hicheri Y, Cordonnier C, Costa JM, Bretagne S.
    J Antimicrob Chemother; 2011 Feb 26; 66(2):371-4. PubMed ID: 21131690
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients.
    Dannaoui E, Meletiadis J, Tortorano AM, Symoens F, Nolard N, Viviani MA, Piens MA, Lebeau B, Verweij PE, Grillot R, And The Ebga Network.
    J Med Microbiol; 2004 Feb 26; 53(Pt 2):129-134. PubMed ID: 14729934
    [Abstract] [Full Text] [Related]

  • 20. Multi-azole resistance in Aspergillus fumigatus.
    Howard SJ, Webster I, Moore CB, Gardiner RE, Park S, Perlin DS, Denning DW.
    Int J Antimicrob Agents; 2006 Nov 26; 28(5):450-3. PubMed ID: 17034993
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.